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Lay summary 
Individuals misusing alcohol who carry a particular variant of the gene PNPLA3 are more at 
risk of developing severe alcoholic hepatitis, a condition with a poor chance of survival.  The 
longer-term outcome in people with this condition who survive the initial illness is strongly 
influenced by their ability to remain abstinent from alcohol.  However, carriers of this gene 
variant are less likely to survive even if they are able to stop drinking completely.  Knowing if 
someone carries this gene variant could influence the way in which they are managed. 
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Abstract 
 
Background & Aims: Carriage of rs738409:G in PNPLA3 is associated with an increased risk 
of developing alcohol-related cirrhosis and has a significant negative effect on survival.  Short-
term mortality in patients with severe alcoholic hepatitis is high; drinking behaviour is a major 
determinant of outcome in survivors.  The aim of this study was to determine whether carriage 
of rs738409:G has an additional detrimental effect on survival in this patient group. 
Methods: Genotyping was undertaken in 898 cases with severe alcoholic hepatitis, recruited 
through the UK Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial, and 1,188 
white British/Irish alcohol dependent controls with no liver injury recruited via University 
College London.  Subsequent drinking behaviour was classified, in cases surviving ≥90 days, 
as abstinent or drinking.  The relationship between rs738409 genotype, drinking behaviour and 
survival was explored. 
Results: The frequency of rs738409:G was significantly higher in cases than controls (29.5% 
vs. 18.9%; p=2.15x10-15; OR 1.80 [95%CI 1.55–2.08]).  Case-mortality at days 28, 90 and 450 
was, 16%, 25% and 41% respectively.  There was no association between rs738409:G and 28-
day mortality.  Mortality in the period day 90-450 was higher in survivors who subsequently 
resumed drinking (Hazard Ratio [HR] 2.77, 95% Confidence Interval [CI] 1.79–4.29; 
p<0.0001) and individuals homozygous for rs738409:G (HR 1.69, 95% CI 1.02–2.81, p=0.04). 
Conclusion: Homozygosity for rs738409:G in PNPLA3 confers significant additional risk of 
medium-term mortality in patients with severe alcoholic hepatitis.  Rs738409 genotype may be 
taken into account when considering treatment options in these patients. 
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Introduction 
Cirrhosis is a major cause of global mortality accounting for around one million deaths per 
annum [1].  Alcohol misuse is the leading cause of cirrhosis in the Western world and is 
responsible for nearly half of cirrhosis-related deaths [2]. 
Alcohol produces a spectrum of liver injury ranging from hepatic steatosis to cirrhosis and 
hepatocellular carcinoma.  Only 15 to 20% of individuals who chronically misuse alcohol 
develop cirrhosis [3,4]; approximately 15% of these individuals will eventually develop 
hepatocellular carcinoma [5.6].  The development of alcohol-related liver injury and its 
evolution to cirrhosis is generally asymptomatic with the majority of individuals presenting 
incidentally.  Symptomatic presentation is associated with hepatic decompensation in patients 
with established cirrhosis or, much less frequently, severe alcoholic hepatitis. 
The clinical syndrome of alcoholic hepatitis is typified by the recent onset of jaundice and 
other features of liver failure in the context of active, chronic and heavy alcohol consumption.  
The severity of the liver injury is conventionally defined by Maddrey’s Discriminant Function 
(DF), a calculation based on the serum bilirubin concentration and prothrombin time [7]; a DF 
≥32 indicates severe disease and carries an adverse prognosis, with mortality rates of 15 to 
30% in the first month [8-11] and upwards of 50% within a year of presentation [9,11-13]. 
Poor short-term prognosis in severe alcoholic hepatitis is associated with high serum bilirubin 
and creatinine, significant prolongation of the prothrombin time, hepatic encephalopathy, 
hypoalbuminaemia and ascites [7,11,14].  The long-term prognosis is influenced by several 
factors including gender, disease severity at presentation, the presence of/evolution to cirrhosis 
and subsequent drinking behaviour [9,12,13,15,16]. 
The role of prednisolone in the management of alcoholic hepatitis remains controversial.  The 
2008 Cochrane meta-analysis reported that corticosteroids significantly reduce 28-day 
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mortality in patients with a DF ≥32 or hepatic encephalopathy [17].  These findings were later 
endorsed by an analysis of individual patient data from five randomized controlled trials [18].  
The Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial [11] did not demonstrate 
a significant reduction in 28-day mortality with prednisolone treatment.  Nevertheless, a recent 
systematic review and network meta-analysis, incorporating the STOPAH data, reported a 
significant reduction in short-term mortality in patients treated with prednisolone [19].  
Treatment has not, however, been reported to reduce medium- or long-term mortality [11,16]. 
The role of genetic polymorphisms in determining liver disease risk and outcome has received 
considerable attention in recent years.  A common single nucleotide polymorphism (rs738409; 
C>G) in the gene patatin-like phospholipase domain containing protein 3 (PNPLA3) results in 
substitution of an isoleucine residue for methionine at position 148 of the protein (Ile148Met; 
I148M).  There is considerable evidence that carriage of the risk allele, rs738409:G, plays an 
important role in determining risk for the development of alcohol-related cirrhosis from 
individual studies [20-23], a meta-analysis [24] and, most recently, a genome-wide 
association study [25].  In addition, rs738409:G has been shown to be a significant risk factor 
for the development of hepatocellular carcinoma in patients with established cirrhosis in 
individual studies [26-30], and in a meta-analysis based on individual patient data [31].  
Furthermore there is growing evidence that rs738409:G influences several other important 
aspects of alcohol-related liver disease; thus, carriage of the G allele is associated with earlier 
development of cirrhosis, independently of the age of onset of at-risk alcohol consumption 
[32]; more rapid progression towards decompensated disease [33]; a reduction in 
transplantation-free survival [33] and poorer outcomes following development of 
hepatocellular carcinoma [34]. 
Although the frequency of rs738409:G was reported to be significantly increased in patients 
with severe alcoholic hepatitis in one small study [35], it is not known whether carriage of this 
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allele otherwise influences the course of the disease or its outcome.  The availability of DNA 
from many of the participants in the STOPAH trial [11] provided an opportunity to explore the 
role of this variant in disease progression and outcome in this patient population.  
The aims of the present study were: 
(i) To identify variables associated with short-term (<28 days) survival in patients with severe 
alcoholic hepatitis, looking specifically at the effect of carriage of rs738409:G in PNPLA3 and 
the response to treatment; 
(ii) To identify variables associated with medium-term (90 to 450 days) survival in this 
population looking specifically at the effect of rs738409:G in PNPLA3; 
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Patients and methods 
Study population 
Cases 
Cases with severe alcoholic hepatitis were recruited as per the STOPAH trial protocol [36].  
DNA samples and matched clinical data were available for 898 of 1103 enrolled patients 
(81.4%).  All had a history of long-standing alcohol misuse; compatible clinical, laboratory 
and/or liver biopsy features of alcoholic hepatitis; no other identified causes for their liver 
disease; and a DF ≥32.  All were British but additional data were collected on self-reported 
ethnicity.  Eight-hundred and sixty patients (95.8%) identified themselves as White, three 
(0.3%) as Black or Black British, 23 (2.6%) as Asian or Asian British, five (0.6%) as mixed 
origin and seven (0.8%) as ‘other’ or not stated. 
Patients were randomized to treatment with prednisolone or pentoxifylline for 28 days using a 
double blind, double dummy design [36].  Randomization was block designed and stratified by 
geographical region and dichotomous risk status with the presence of sepsis, gastrointestinal 
bleeding or renal failure prior to randomization defining high-risk. 
Individuals who survived the initial hospitalisation were further evaluated at 90 days and at one 
year to ascertain clinical status particularly in relation to their self-reported alcohol use.  
Patients were consented for follow-up via the NHS Information Centre Data Linkage service 
ensuring ongoing follow-up and reliable capture of mortality data. 
Ethical approval was granted for this study by the Wales Research Ethics Committee (REC 
09/MRE09/59).  The study was conducted according to the Declaration of Helsinki (Hong 
Kong Amendment) and Good Clinical Practice (European guidelines).  All participants, or 
their legally appointed representatives, provided written informed consent. 
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Controls 
Controls with a background of alcohol dependence but with no evidence of liver injury 
(n=1,188) were recruited via the University College London Consortium.  The majority had 
been drinking hazardously for over 15 years and were actively drinking at the time of 
enrolment.  In approximately one-third the absence of significant alcohol-related liver injury 
was confirmed on liver biopsy.  The remainder had no historical, clinical or radiological 
features suggestive of significant liver injury either at presentation or during prolonged follow-
up.  All were of English, Scottish, Welsh or Irish descent with a maximum of one grandparent 
of white European Caucasian origin.  None of the individuals was related. 
United Kingdom National Health Service Multicentre Research Ethics Committee approval 
was granted for this study (MREC/03/11/090).  This was ratified by local ethics committees 
associated with individual participating centres.  All participants provided written informed 
consent. 
PNPLA3 Genotyping 
Genotyping for rs738409 in PNPLA3 was performed using the K-Biosciences Competitive 
Allele Specific PCR (LGC Genomics, Hoddesdon, UK) platform with amplification and 
detection undertaken using a LightCycler® 480 real-time PCR system (Roche Molecular 
Diagnostics, Burgess Hill, UK).  Genotype calling was performed automatically using 
proprietary software with minor manual editing of genotype calls.  Approximately 12% of 
samples, randomly selected a priori, were genotyped in duplicate to ensure consistent genotype 
calling. 
Data processing and statistical analyses 
Routinely collected demographic and laboratory data were used to calculate prognostic scores 
viz: The Model for End-Stage Liver Disease (MELD), [37]; the Glasgow Alcoholic Hepatitis 
Score (GAHS), [38] and the Lille score [39]. 
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Patients self-categorised their current drinking behaviour at day 90 as (i) abstinent; (ii) drinking 
at low levels: men ≤24g/day; women: ≤16 g/day; (iii) drinking at moderate levels: men >24 but 
≤60g/day; women >16 but ≤40 g/day; (iv) drinking at high levels: men >60g/day; women 
>40g/day.  For purposes of statistical analysis patients were classified as either abstinent (i) or 
drinking (ii-iv).  However, in view of the relatively high incidence of missing data on drinking 
behaviour at the day 90 and 1-year time points additional sensitivity analyses were undertaken 
based upon the following: 
1. Reclassification of drinking behaviour at day 90 in light of additional information at 1 
year, where available; 
2. Assumption that individuals in whom information on drinking behaviour was not 
available at day 90, for any reason, had returned to drinking; 
Tests for primary allelic associations, missingness and deviation from Hardy-Weinberg 
equilibrium, were performed using PLINK v1.9 [40, 41].  Samples with conflicting calls were 
excluded from further analysis. 
The influence of genotype on patient characteristics at presentation, including prognostic 
scores, was tested using Kruskall-Wallis or Chi-square tests across all three groups. 
The STOPAH trial showed no beneficial effect of pentoxifylline on outcome in cases with 
severe alcoholic hepatitis but a modest benefit from use of prednisolone [11].  Thus, treatment 
effects were examined dichotomously viz. treatment with prednisolone (cases treated with 
prednisolone plus placebo and prednisolone plus pentoxifylline: n=429) or no treatment with 
prednisolone (cases treated with pentoxifylline plus placebo or placebo plus placebo: n=438). 
Survival times, and mortality endpoints, were calculated with respect to the treatment start date 
or, if not recorded, the date of randomization.  A data cut-off of 450 days was applied because 
the large variation in follow-up times engendered a risk of informative censorship, 
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disproportionate censorship between genotypic groups and the likely impact of additional 
factors such as delayed return to drinking and development of co-morbid disease on longer-
term survival, about which little or no information was available. Thus, cases were censored at 
the time of liver transplantation, the limit of follow-up or day 450, whichever occurred first.   
Cox proportional hazards models were used to test associations between explanatory variables 
and survival and interactions between explanatory variables in relation to survival. Where 
significant interactions were found univariate and multivariate analyses were undertaken in 
relevant population sub-groups to better understand the main effects of the covariates on 
outcome. Tests of genotypic association were performed using three models of inheritance 
additive (CC [0]. CG [1] and GG [2]; pADD), recessive (CC+CG vs. GG, pREC) and dominant 
(CC vs. CG+GG; pDOM); the model showing the greatest statistical significance was used in 
subsequent multivariable analysis.  Separate models were fitted for clinically relevant features 
and biochemical parameters.  Variables demonstrating marginal statistical significance (p<0.1) 
in univariate analyses were included in multivariable analyses. These models were fitted by 
backward elimination with a cut-off (p=0.05).  Where a composite variable and its constituents 
were both associated with outcome only the most significantly associated was incorporated 
into the multivariable analysis in order to reduce co-linearity. 
Statistical analyses were performed using SPSS version 22 (IBM, Armonk, USA). Survival 
curves were plotted in R [42] using the packages ggplot2, survival, gridExtra, reshape and plyr.
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Results 
Genotyping accuracy 
The overall genotyping rate was 98%.  Genotypes were successfully called in 867 (97%) of 
898 case samples and in 1,175 (99%) of the 1,188 control samples.  Two samples (<0.05% of 
total) demonstrated conflicting genotypes and were excluded.  The marker followed Hardy-
Weinberg equilibrium in both case and control populations (p>0.05). 
PNPLA3 allelic association analysis 
A significant increase in the frequency of rs738409:G was observed in cases compared with 
controls (allelic p=2.15x10-15, Odds Ratio [OR] 1.80: 95% Confidence Intervals [CI] 1.55–
2.08) (Table 1). 
PNPLA3 association with baseline demography and assessment variables  
There were no significant differences in age, gender distribution, alcohol consumption, or the 
majority of the clinical or laboratory variables at baseline in relation to rs738409 genotype 
(Supplementary Table 1). 
Survival data 
Survival data were available for all 867 genotyped cases; the median (range) duration of 
follow-up was 844 (352-1452) days.    
Overall 52 cases (6.2%) were censored because their duration of follow-up was too short; two 
patients (0.2%) underwent orthotopic liver transplantation at days 215 and 359 post-enrolment 
while 360 (41.5%) died during the follow-up period; the mortality rates at days 28, 90 and 450 
were, 15% (131/864), 25% (216/861) and 44% (360/813) respectively. 
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Impact of genotype on treatment response and short term survival 
One-hundred and thirty-one (15.0%) of the 867 cases with severe alcoholic hepatitis had died 
by day 28 while a further three were lost to follow-up.  There was no significant relationship 
between 28–day mortality and rs738409 genotype (PADD = 0.95, PDOM = 0.88, PREC = 0.64; 
Figure 1, Table 2).  Treatment with prednisolone was associated with a decreased risk of 
mortality compared with placebo (Hazard Ratio [HR]=0.67; 95% CI 0.48–0.95, p=0.03).  No 
significant interaction was detected between rs738409 genotype and prednisolone treatment in 
relation to 28-day mortality. 
Cox proportional hazards regression analysis identified randomisation risk, treatment with 
prednisolone, age, the presence of overt hepatic encephalopathy, total white blood cell and 
neutrophil counts, blood urea, INR, serum bilirubin and creatinine as significantly associated 
with 28-day mortality (Table 3). 
Multivariable Cox regression analysis, incorporating the variables associated on univariate 
analysis (p <0.1), together with a term for homozygosity for rs738409:G, confirmed 
significant, independent associations with 28-day survival for many of the variables identified 
in univariate analyses, including prednisolone treatment; homozygosity for rs738409:G was 
not independently associated (Table 3). 
Impact of genotype on prognostic scoring systems 
There were no differences in the distributions of the prognostic scores calculated at baseline or 
the Lille score at day 7 in relation to rs738409 genotype (Table 4).  All four of the commonly 
used scoring systems were significantly associated with 28-day mortality.  The Lille score had 
the highest predictive accuracy (Supplementary Table 2). No statistically significant 
interactions were found between any of the scoring systems and rs738409 genotype in relation 
to 28-day mortality. 
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Impact of genotype and drinking behaviour on medium-term survival 
There was no impact of rs738409 genotype on 90-day survival.  However, in the cohort of 
patients surviving beyond this time-point, homozygosity for rs738409:G was associated with a 
significant decrease in survival at day 450 (GG: 34.7% (17/49); CG: 21.8% (53/243); CC: 
25.1% (74/295); pREC = 0.04; [HRREC 1.69, 95% CI 1.02 – 2.81];  pADD = 0.62; pDOM = 0.67) 
(Fig 2A). 
Information on drinking behaviour post hospital discharge was available in 397 (46%) of the 
867 cases with severe alcoholic hepatitis at day 90 and in 174 (20.1%) at one year.  Reported 
abstinence rates were 65% and 57% respectively.  Significant differences in survival to day 
450 were observed in relation to drinking behaviour recorded at day 90 (Fig 2B; mortality in 
those who were drinking was 35.3% (47/133) vs. 14.3% (35/244) in those classified as 
abstinent (HR 2.77, 95% CI 1.79–4.29; p<0.00001).  This association were robust to the 
incorporation of the additional data on drinking behaviour collected at 1 year. This approach 
may be prone to bias due to potential conditioning on the future, however the association 
remained in additional sensitivity analysis where all cases with missing data at day 90 were 
assumed to have resumed drinking (Supplementary Table 3). 
The association between rs738409 homozygosity and 450-day survival was independent of a 
return to drinking (Supplementary Table 4). Statistically significant interactions were identified 
between drinking behaviour and both serum bilirubin (p=0.004) and neutrophil count 
(p=0.002) at day 90 in relation to medium-term survival. Interactions between drinking 
behaviour and homozygosity for rs738409:G (p=0.1) and the INR at day 90 (p=0.09) did not 
reach statistical significance.  In view of these interactions, factors influencing medium-term 
survival were examined separately in groups defined by drinking status. 
In cases reporting drinking at day 90, homozygosity for rs738409:G had no statistically 
significant effect on survival; mortality rates were around 30% in all three genotypic groups 
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over the 90 to 450 day period (Fig 2C).  This lack of effect was confirmed on multivariable 
regression (Table 5).  However, in cases reporting abstinence at day 90 homozygosity for 
rs738409:G was associated with a significantly higher mortality during the follow-up period 
(GG: 36.4% (8/22); CG 12.1% (13/107); CC 12.2% (14/115); HR 3.40, 95% CI 1.54–7.49, 
p=0.002) (Fig 2D).  Cox multivariable regression analysis confirmed that homozygosity for 
rs738409:G was significantly and independently associated with reduced survival in this group 
(HR 2.56, 95% CI 1.03–6.34, p = 0.04) (Table 6). 
These differences were maintained when drinking behavior was further refined based on the 
data collected at 1 year.  Analyses undertaken assuming that patients in whom data on drinking 
behaviour at day 90 were not available had resumed drinking confirmed significant 
independent associations with 450-day survival for both homozygosity for rs738409:G and 
drinking behaviour, as well as revealing a statistically significant interaction between the two 
(Supplementary Table 5). 
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Discussion 
The variant rs738409:G in PNPLA3 has been consistently associated with the risk of 
developing alcohol-related cirrhosis, and has been implicated in more rapid disease progression 
and the risk of developing hepatocellular carcinoma [23,29, 30-32].  Severe alcoholic hepatitis 
has considerable associated mortality [8, 9, 11-13] but apart from one small series, published in 
abstract form [33], which identified rs738409:G as a risk factor for developing severe alcoholic 
hepatitis, the potential impact of this genetic polymorphism on disease presentation, 
progression and outcome has not been evaluated.  The results of the present study have helped 
clarify these associations. 
First: this study identifies rs738409:G as a risk factor for the development of severe alcoholic 
hepatitis.  Many of the included cases had co-existing alcohol-related cirrhosis and a high 
proportion of the remainder are likely to develop cirrhosis over time.  This finding is not, 
therefore, surprising but given the size and appropriateness of the case and control populations 
it provides robust confirmation of the results of a previous much smaller study. 
Second: there is no evidence that rs738409 genotype plays a role in determining the onset 
timing, mode of presentation or severity of alcoholic hepatitis.  Thus the age, gender 
distribution, the quantity of alcohol consumed, the duration of alcohol misuse and disease 
severity, assessed using the available scoring systems, were similar in all subgroups defined, 
by genotype. 
Third: there is no evidence that the rs738409 genotype is associated with short-term mortality 
in patients with severe alcoholic hepatitis, nor does it interact with the severity of liver disease, 
prednisolone treatment or early improvement in liver function, as measured by the Lille score 
in relation to short-term mortality. 
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Fourth: the study provides clear evidence supporting the primacy of drinking behaviour as a 
determinant of medium-term outcome in patients with severe alcoholic hepatitis who survive 
the initial illness [15, 16].  Individuals who maintain abstinence have significantly lower 
mortality than individuals who resume drinking, at any level.  Resumption of alcohol 
consumption also appears to influence the relative associations of several variables with 
survival, particularly neutrophil count and serum bilirubin. 
Fifth: rs738409 genotype influences medium-term survival. Thus, in the entire population 
surviving beyond day 90 taken as a whole, mortality was significantly higher in individuals 
homozygous for the G allele.  Sensitivity analyses, conducted on the assumption of resumed 
drinking where data were missing, showed that the independent associations of both drinking 
behaviour and homozygosity for rs738409:G with survival were robust. This relationship may 
not be entirely straight forward as there is evidence of an interaction with drinking behaviour, 
albeit only significant on sensitivity analysis in this population. Thus, while there was no 
difference in mortality, by genotype, in individuals who continued to drink, abstinence from 
alcohol was associated with improved survival in heterozygote carriers of rs738409:G or non-
carriers but not in patients homozygous for rs738409:G. This suggests the effect of rs738409 
genotype is subservient to drinking behaviour in those who continue to drink. 
This study has a number of limitations viz.: (i) The information on drinking behaviour was 
based on self-reported estimates of alcohol intake collected on day 90 and these data were only 
available for 46% of the cases; data were only available in 21% of survivors at one year.  
Sensitivity analyses were conducted to evaluate the potential effect on findings based upon 
adjustment of drinking status based upon 1-year data and assumption of resumed drinking in 
those of unknown status. The results of the subsequent analyses show clear differentiation in 
the direction expected supporting this stance and indicate our findings are robust. (ii) A small 
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proportion of cases were of non-British ancestry (n=38, 4.2%).  There are ethnic differences in 
the frequency of rs738409:G but its association with an increased risk of developing alcohol-
related liver disease is consistent across ethnic groups.  Thus, inclusion of these individuals in 
the analyses is unlikely to have confounded the results to any appreciable degree; (iii) survival 
data were captured using the NHS database of registered deaths but registration is often 
delayed, and deaths occurring outside the UK are not registered; thus the number of deaths 
may have been underestimated; (iv) data on the number of cases undergoing liver 
transplantation were only captured for the duration of the STOPAH trial, although it is likely 
that numbers transplanted beyond this immediate time-point would have been small; (v) 
although the number of cases was large the number of individuals homozygous for rs738409:G 
was relatively small and this may have limited the power. 
In conclusion: individuals with severe alcoholic hepatitis who survive the acute event and are 
homozygous for rs738409:G in PNPLA3 would appear to be at increased risk of mortality in 
the medium term, even if they attain and maintain abstinence from alcohol.  Genotyping 
rs738409 in PNPLA3 will identify these individuals and could be taken into account in clinical 
decision-making, potentially allowing these particularly vulnerable individuals to be 
considered early for liver transplantation or novel therapies.  The need to employ measures to 
assist patients with severe alcoholic hepatitis to attain and maintain abstinence is highlighted as 
of critical importance. 
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Legends to figures 
 
Fig. 1. Twenty-eight day survival in cases with severe alcoholic hepatitis stratified by 
rs738409 genotype. There is no impact of rs738409 genotype on short-term survival. 
Fig. 2. Medium-term survival in cases with severe alcoholic hepatitis surviving at least 90 
days. (A) Mortality was increased in cases homozygous for rs738409:G (GG: 34.7%; CG: 21.8%; 
CC: 25.1%; HR 1.69, 95% CI 1.02 – 2.81%; pREC=0.04).  (B) Patients reporting alcohol 
consumption at day 90 have increased mortality at day 450 compared to those reporting abstinence 
(35.3% vs. 14.3% (HR 2.77, 95% CI 1.79–4.29; p<0.00001). (C) In cases who resumed drinking 
genotype did not affect outcome; (D) In cases who attained abstinence, survival was reduced in 
rs738409:G homozygotes (GG: 36.4%; CG 12.1%; CC 12.2%; HR 3.40, 95% CI 1.54–7.49, 
pREC=0.002). 
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Table 1. Genotype frequencies and association analysis of rs738409 in cases with severe 
alcoholic hepatitis and controls with alcohol dependence but no liver injury 
 
 
 
Abbreviations: SNP: single nuclear polymorphism; MAF: Minor Allele Frequency; OR: Odds ratio; CI: 
Confidence Interval 
 
SNP 
 
Cases 
(n=867) 
Controls 
(n= 1175) 
Cases vs. controls 
Genotype count 
CC/CG/GG 
MAF 
(%) 
Genotype count 
CC/CG/GG 
MAF 
(%) 
Significance 
(p) 
OR 
(95% CI) 
rs738409 425/372/70 29.5 772/362/41 18.9 2.15x10-15 1.80 (1.55-2.08) 
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Table 2: Twenty-eight day mortality in cases with severe alcoholic hepatitis, by treatment 
allocation and rs738409 genotype 
 
 
Treatment 
allocation 
Cases 
(n) 
Overall deaths 
(n: %) 
Deaths, by rs734809 genotype  
(n: %) 
CC CG GG 
Prednisolone 
429 53  
(12.4%) 
25 
(11.8%) 
22 
(12.3%) 
6  
(15.4%) 
No prednisolone 
438 78  
(17.8%) 
40 
(18.7%)  
32 
(16.6%) 
6  
(19.4%) 
Total   
867 131  
(15.1%) 
65  
(15.3%) 
54  
(14.5%) 
12  
(17.1%) 
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Table 3: Variables associated with 28-day mortality in cases with severe alcoholic hepatitis 
 
Variable 
Univariate Multivariable 
HR 95% CI Significance (p) HR 95% CI 
Significance 
(p) 
Age 1.05 1.04 – 1.07 <0.001 1.04 1.02 – 1.07 <0.001 
Gender 0.88 0.74 – 1.06 0.19    
Alcohol 
consumption§ 1.00 0.99 – 1.00 0.10    
Overt hepatic 
encephalopathy 2.85 2.02 – 4.02 <0.001 2.46 1.55 – 3.90 <0.001 
White cell count* 
(x106/mm3) 1.08 1.06 – 1.11 <0.001    
Neutrophils 
(x106/mm3) 1.09 1.06 – 1.12 <0.001 1.06 1.02 – 1.09 0.001 
Bilirubin  
(µmol/l) 1.003 1.002 – 1.005 <0.001 1.001 1.000 – 1.003 0.09 
Aspartate 
transaminase (IU/l)§ 1.002 1.000 – 1.005 0.09    
Alkaline 
phosphatase (IU/l) 0.999 0.997 – 1.001 0.45    
Albumin 
(g/l) 0.99 0.97 – 1.02 0.67    
Urea  
(mmol/l) 1.09 1.07 – 1.12 <0.001 1.11 1.07 – 1.15 <0.001 
Creatinine 
(µmol/l)§ 1.01 1.008 – 1.013 <0.001    
International 
normalised ratio 1.21 1.06 – 1.38 0.004 1.27 1.06 – 1.51 0.009 
Randomisation risk§ 1.51 1.26 – 1.81 <0.001    
rs738409:G 
homozygosity§ 1.15 0.64 – 2.09 0.64    
Prednisolone 0.67 0.48 – 0.95 0.03 0.59 0.37 – 0.93 0.02 
Abbreviations: HR: Hazard Ratio; CI: Confidence Intervals 
* Variable not entered into the Cox multivariable analysis due to co-linearity (more significantly associated 
constituent part of variable exists) 
§ Variable excluded from the Cox multivariable analysis by backward elimination due to lack of significant 
independent association 
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Table 4: Prognostic scores in cases with severe alcoholic hepatitis, by rs738409 genotype 
 
Prognostic 
scoring system 
PNPLA3 rs738409 Genotype Significance 
 
(p) CC 
(n = 425) 
CG 
(n = 372) 
GG 
(n = 70) 
Baseline DF7 62±29 62±25 64±27 0.50 
Baseline MELD37 21±6 21±6 21±7 0.53 
Baseline GAHS38 8±1 8±1 8±1 0.41 
 
CC 
(n = 292) 
CG 
(n = 246) 
GG 
(n = 37)  
Lille*39 0.46±0.3 0.49±0.3 0.43±0.3 0.55 
Lille response 
(<0.45) 158 (54.1%) 119 (48.3%) 23 (62.2%) 0.19 
Data expressed as mean ± 1SD or as number (%) *n=575 
Abbreviations:  
DF: Discriminant function calculated as 4.6 × (patient prothrombin time [s] − control prothrombin time [s]) + 
(serum bilirubin [µmol/l]/17.1); scores > 32 indicate severe disease  
MELD: Model for End-Stage Liver Disease: scores range from 6 to 40, with higher scores indicating worse 
prognosis  
GWAS: The Glasgow Alcoholic Hepatitis Score: ranges from 5 to 12, with higher scores indicating worse 
prognosis  
Lille: Composite scoring system incorporating age, serum albumin and bilirubin levels at baseline and 7 days 
after the start of treatment. A score of > 0.45, 7 days after initiation of treatment predicts an adverse outcome. 
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Table 5: Variables associated with 450-day mortality in cases with severe alcoholic hepatitis 
who resumed alcohol consumption 
Variable  Univariate Multivariable 
HR 95% CI Significance 
(p) 
HR 95% CI Significance 
(p) 
Age 1.04 1.00 – 1.07 0.04    
Gender 1.68 0.95 – 2.98 0.08 2.02 1.05 – 3.90 0.04 
Overt hepatic 
encephalopathy 2.34 1.12 – 4.90 0.02    
White cell count* 
(x106/mm3) 1.07 1.00 – 1.13 0.04    
Neutrophils§ 
(x106/mm3) 1.09 1.02 – 1.17 0.01    
Bilirubin  
(µmol/l) 1.004 1.002 – 1.006 <0.001 1.005 1.002 – 1.007 <0.001 
Aspartate 
transaminase 
(IU/l)† 
1.01 1.001 – 1.011 0.01    
Alkaline 
phosphatase (IU/l) 1.002 1.000 – 1.004 0.03 1.002 1.000 – 1.005 0.03 
Albumin  
(g/l) 0.94 0.90 – 0.99 0.01    
Urea  
(mmol/l) 1.22 1.10 – 1.35 <0.001 1.23 1.10 – 1.38 <0.001 
Creatinine§ 
(µmol/l) 1.02 1.01 – 1.03 0.005    
International 
normalised ratio 1.00 0.81 – 1.24 0.98    
Randomisation 
risk 0.71 0.42 – 1.18 0.19    
rs738409 
homozygosity§ 0.88 0.21 – 3.63 0.86    
Prednisolone 0.75 0.42 – 1.33 0.32    
Abbreviations: HR: Hazard Ratio; CI: Confidence Intervals; AST: Aspartate transaminase; ALP: Alkaline 
phosphatase 
* Variable not entered into the multivariable analysis due to co-linearity (more significantly associated constituent part 
of variable exists) 
§ Variable excluded from the multivariable analysis by backward elimination due to lack of significant independent 
association 
†Variable not entered into multivariable analysis due to significant missing information (>10%) 
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Table 6: Variables associated with 450-day mortality in cases with severe alcoholic hepatitis 
who maintained abstinence from alcohol 
Variable  Univariate Multivariable 
HR 95% CI Significance (p) HR 95% CI 
Significance 
(p) 
Age§ 1.06 1.03 – 1.10 0.001    
Gender 0.91 0.45 – 1.83 0.79    
Overt hepatic 
encephalopathy 2.11 0.81 – 5.46 0.13    
White cell count* 
(x106/mm3) 1.25 1.13 – 1.38 <0.001    
Neutrophils 
(x106/mm3) 1.33 1.19 – 1.49 <0.001 1.22 1.06 – 1.41 0.005 
Bilirubin  
(µmol/l) 1.01 1.01 – 1.02 <0.001 1.007 1.002 – 1.012 0.006 
Aspartate 
transaminase 
(IU/l) 
1.01 0.99 – 1.03 0.17    
Alkaline 
phosphatase§ 
(IU/l) 
1.006 1.001 – 1.010 0.02    
Albumin  
(g/l) 0.90 0.86 – 0.94 <0.001 0.92 0.88 – 0.97 0.002 
Urea§  
(mmol/l) 1.25 1.14 – 1.37 <0.001 1.15 1.03 – 1.29 0.02 
Creatinine§  
(µmol/l) 1.01 1.005 – 1.023 0.003    
International 
normalised ratio 1.23 1.10 – 1.39 0.001 1.24 1.08 – 1.42 0.003 
Randomisation 
risk§ 1.36 0.94 – 1.96 0.1    
rs738409 
homozygosity 3.40 1.54 – 7.49 0.002 2.56 1.03 – 6.34 0.04 
Prednisolone 1.29 0.66 – 2.52 0.46    
Abbreviations: HR: Hazard Ratio; CI: Confidence Intervals; AST: Aspartate transaminase; ALP: Alkaline 
phosphatase 
*Variable not entered into multivariable analysis due to significant co-correlation with another variable 
§Variable excluded from the multivariable analysis by backward elimination due to lack of significant association 
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